mavrilimumab   Click here for help

GtoPdb Ligand ID: 7785

Synonyms: CAM-3001 | KPL-301
Immunopharmacology Ligand
Compound class: Antibody
Comment: Mavrilimumab targets CSF2RA (aka GM-CSFRα).
Peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis identifies mavrilimumab as antibody 6 in patent US8263075 [2].
Click here for help
No information available.
Summary of Clinical Use Click here for help
A phase 2 clinical trial (NCT01712399) of mavrilimumab in adult rheumatoid arthritis (RA) patients has been completed (May 2017). In these patients mavrilimumab produced a rapid and prolonged reduction in interleukin-6 production which is indicative of suppression of tissue inflammation. Further development in RA has been discontinued, however Kiniksa Pharmaceuticals are actively evaluating mavrilimumab (which they have re-coded as KPL-301) in a Phase 2 trial in patients with giant cell arteritis (GCA) [3].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through the activation, differentiation, and survival of macrophages and neutrophils. Antibody binding results in decreased GM-CSF-induced activation of the GM-CSFRα. This helps to reduce neutrophil derived TNFα, and induces clinical remission and reduce flares in patients with RA [4].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01712399 A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis Phase 2 Interventional MedImmune LLC
NCT03827018 KPL-301 for Subjects With Giant Cell Arteritis Phase 2 Interventional Kiniksa Pharmaceuticals, Ltd.